Abstract 270P
Background
The companion diagnostic for olaparib against prostate cancer, which aims to detect BRCA1 or BRCA2 gene (BRCA1/2) variants, was investigated in December 2020 in Japan. There have been no reports on germline BRCA1/2 variants in actual clinical practice. Here, we evaluate germline BRCA1/2 variants and their relationship to the clinical characteristics and outcomes in prostate cancer.
Methods
Between June 2021 and June 2023, 92 patients with prostate cancer were examined using germline BRCA1/2 testing. Further, the associations between pathogenic variants and clinical outcomes were assessed.
Results
Of the 92 patients referred from the Iwate prefecture in Japan for genetic testing, six patients (6.5%) carried germline pathogenic variants; BRCA2 was the most frequent (n=5, 5.4%), followed by BRCA1 (n=1, 1.1%). Among the six variants in BRCA2, p.Ala338Valfs*11 was identified for the first time. Patients with the BRCA1/2 variant exhibited poor outcomes for overall survival from castration-resistant prostate cancer (CRPC), first-line androgen receptor-axis-targeted therapy (ARAT) for CRPC, and taxane chemotherapy (hazard ratio [HR] 4.77, 95% CI: 1.00 to 22.6, P=0.049; HR=5.27, 95% CI: 1.77 to 15.7, P=0.0028; and HR=7.47, 95% CI: 1.49 to 37.4, P=0.014, respectively).
Conclusions
In this study, patients with prostate cancer possessing germline variants of BRCA1/2 genes exhibited poor clinical response to ARAT for CRPC and taxane chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Presenter: Sam Martin
Session: Poster Display
Resources:
Abstract
624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy
Presenter: Lu Pan
Session: Poster Display
Resources:
Abstract
625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population
Presenter: Kyae Hyung Kim
Session: Poster Display
Resources:
Abstract
626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience
Presenter: Jisook Yim
Session: Poster Display
Resources:
Abstract
627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020
Presenter: Taha Nagib
Session: Poster Display
Resources:
Abstract